What is ORIC Pharmaceuticals, Inc. (ORIC)?

ORIC Pharmaceuticals, Inc. (ORIC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ORIC?

The current price of ORIC is $9.30. Prices are updated in real time on Stocks360.

What is ORIC's price-to-earnings (PE) ratio?

ORIC's trailing twelve-month PE ratio is -6.89, based on current price and earnings per share data available on Stocks360.

What is ORIC's market capitalization?

ORIC's market capitalization is $963,969,701.00, placing it in the small-cap tier.

ORIC Pharmaceuticals, Inc. (ORIC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.30

Market Cap

$963.97M

PE (TTM)

-6.89

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.98

Day Range

$8.60 – $9.33

52-wk Range

$7.23 – $14.68

Avg Volume

N/A

Volume

1.41M

ORIC Pharmaceuticals, Inc. (ORIC) is a publicly traded company in the Healthcare sector. Latest price: $9.30. Market cap $963.97M. Trailing PE -6.89. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $12.93 2026-10-28 · $9.30 (-28.07%)

Earnings

Most Recent

Aug 3, 2026

EPS $-0.38 vs est. $-0.36

Missed by $0.02

Next Earnings

Nov 12, 2026

EPS estimate $-0.38

Proprietary Signals

Signal snapshot temporarily unavailable.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.89×
P/S (TTM)	0.00×
P/B	2.63×
P/FCF (TTM)	-8.57×
EV / EBITDA	-6.50×
EV / Sales	0.00×
Earnings Yield	-13.97%
Free Cash Flow Yield	-11.66%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$929.81M
Net Income (TTM)	-$134.69M
Free Cash Flow (TTM)	-$112.48M
Net Debt	-$34.16M
Working Capital	$252.94M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-35.35%
Return on Invested Capital	-40.32%